AACR 2023: YH013, a Novel Bispecific EGFR x MET Antibody-Drug Conjugate, Exhibits Potent Anti-Tumor Efficacy
Conclusions YH013 is a novel fully-human bsADC generated from the RenLite® platform that target EGFR and c-Met, which are co-expressed in a wide range of…
Read more
AACR 2023: Targeting Intracellular Tumor Antigens Using Fully Human TCR Mimic Antibodies Derived From HLA Transgenic RenMice
Conclusions Biocytogen’s TCR-mimic (TCRm) antibody platform can be deployed to generate antibodies in vivo to target pHLA complexes for mutated proteins, viral oncoproteins, and cancer-testis…
Read more
AACR 2023: B-hCD94/hNKG2A Mice Provide a Preclinical Tool for Evaluating Therapeutic Antibodies Targeting Human NKG2A
Used in this poster: B-hCD94/hNKG2A mice Conclusions mRNA expression analysis: Mouse Cd94 and Nkg2a mRNAs were detected in splenocytes isolated from wild-type mice, while human…
Read more
AACR 2023: A Novel Triple Humanized B-hPD-1/hPD-L1/hCCR8 Mouse Model to Evaluate In vivo Efficacy of Combination Therapies
Used in the poster: B-hPD-1/hPD-L1/hCCR8 mice Conclusions Protein expression analysis: Human PD-1, PD-L1 and CCR8 proteins were detected in homozygous B-hPD-1/hPD-L1/hCCR8 mice, but not in…
Read more
AACR 2023: *Novel Preclinical Candidates Targeting B7-H3, 6B5 and 10F7, Are Suitable for Development Into Various Drug Modalities
Conclusions 6B5 and 10F7, two anti-human B7-H3 clones, are preclinical candidates suitable for different modalities of B7-H3-targeted therapies. 6B5 is a high affinity, highly B7-H3-selective,…
Read more
AACR 2023: D02, A Novel, Non-Blocking Antibody Targeting IL2RA, Exhibits Significant Anti-Tumor Activity in IL2RA-Humanized Mice
Conclusions D02 is a fully human IgG1 antibody specific to IL2RA that was obtained from RenMabTM humanized immunoglobulin mice. D02 binds both human and cynomolgus…
Read more
ASCO 2022: A phase I open-label dose escalation of YH003 (CD40 mAb) in combination with toripalimab (PD-1 mAb) in patients with advanced solid tumors
YH003, a recombinant, humanized agonistic anti-CD40 IgG2 monoclonal antibody (mAb) specifically recognizes and agonizes CD40 on the antigen-presenting cells to enhance immune responses. Preclinical data…
Read more
ASCO 2022: A first-in-human phase I dose escalation of YH001 (CTLA-4 mAb) in combination with PD-1 mAb in patients with advanced solid tumors
YH001 is a humanized anti-hCTLA-4 IgG1 mAb that relieves CTLA-4-mediated immunosuppression, and thereby enhances the T-cell-mediated antitumor immune response. Pre-clinical data have shown potent anti-cancer…
Read more
AACR 2022: YH012, a Novel Bispecific Anti-HER2 and TROP2 Antibody-Drug Conjugate, Exhibits Potent Antitumor Efficacy
Conclusions YH012 is a novel bispecific HER2/TROP2 antibody-drug conjugate (BsAb-ADC) developed using the RenLiteTM platform. The TAAs HER2 and TROP2 are highly co-expressed in a…
Read more
AACR 2022: Generation of TCR-like fully human antibodies against HLA-antigen-peptide complexes using HLA transgenic RenMice
Conclusions We describe an HLA transgenic mouse that acquires fully human TCR mimic antibodies through a proprietary immunization procedure. Beacon on-chips screening and high-throughput binding…
Read more